[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Nunes J, Tato Marinho R, Raposo J, Velosa J: [Influence of hepatitis C virus replication on splenic lymphoma with villous lymphocytes]. Acta Med Port; 2010 Sep-Oct;23(5):941-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of hepatitis C virus replication on splenic lymphoma with villous lymphocytes].
  • [Transliterated title] Influência da replicação do vírus da hepatite C em linfoma esplénico de células vilosas.
  • The association between hepatitis C and B-cell non-Hodgkin lymphoma (NHL) has been suggested by several studies.
  • We report the case of a 70 year-old patient with the diagnosis of chronic hepatitis C and splenic lymphoma with villous lymphocytes, who had undergone splenectomy and chemotherapy with fludarabine, with transient effectiveness.
  • He was sent to our Hepatology Clinic for the treatment of hepatitis C, and Pegylated Interferon and Ribavirin were started.
  • He had virological and hematological response (63% of villous lymphocytes in the peripheral blood at the beginning of therapy and 0% at the end).
  • With the suspension of antiviral therapy, recurrence of HCV infection and reappearance of atypical lymphocytes (24%) were observed, and Pegylated Interferon was restarted, with good response.
  • The relationship between viral and hematologic response (remission and relapse) supports the hypothesis that hepatitis C virus has an active role in the pathogenesis of splenic lymphoma with villous lymphocytes.
  • [MeSH-major] Hepacivirus / physiology. Lymphoma / virology. Splenic Neoplasms / virology. Virus Replication

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21144339.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


2. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D: Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol; 2003 Mar;120(5):759-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients.
  • Splenic lymphoma with villous lymphocytes (SLVL) is a low-grade B-cell lymphoma defined in the World Health Organization classification as the leukaemic form of splenic marginal zone lymphoma.
  • Presenting features and response to therapy have been described, but information on prognostic factors is scanty.
  • Diagnosis was made on clinical, morphological and immunophenotypic features and, where available, bone marrow and spleen histology.
  • While 27% of patients remained untreated, 10% transformed to high-grade lymphoma.
  • However, only anaemia and lymphocytosis > 16 x 10(9)/l remained highly significant independent prognostic factors when only deaths due to lymphoma were analysed.
  • Splenectomized patients fared better than those receiving chemotherapy only (P = 0.001 for SLVL deaths).
  • We conclude that SLVL is mainly a disease of the elderly with a relatively benign course but, when treatment is required, splenectomy is beneficial.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma, B-Cell / surgery. Splenic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Splenectomy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2003 Oct;123(2):370-1 [14531926.001]
  • (PMID = 12614206.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Grosskreutz C, Troy K, Cuttner J: Primary splenic lymphoma: report of 10 cases using the REAL classification. Cancer Invest; 2002;20(5-6):749-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma: report of 10 cases using the REAL classification.
  • Primary splenic lymphoma (PSL) is rare with a reported incidence of less than 1%.
  • Our objective was to evaluate staging (using the Ahmann and Kehoe criteria), prognosis using the International Prognostic Index (IPI), and pathology using the Revised European-American Lymphoma Classification (REAL) classification.
  • Eight of the 10 patients had diffuse large cell lymphoma (DLCL).
  • Lymph node involvement beyond the splenic hilum seen by imaging studies represents an advanced non-Hodgkin's lymphoma and should be included no longer in the staging of PSL.
  • Eight of the nine patients received chemotherapy following splenectomy.
  • Splenectomy followed by combination chemotherapy, results in excellent long-term survival in PSL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Splenectomy. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197231.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Lefrère F, Hermine O, François S, Panelatti G, Valensi F, Grosbois B, Misset JL, Varet B, Troussard X: Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma; 2000 Dec;40(1-2):113-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is a B-cell chronic lymphoproliferative disorder.
  • Splenectomy and/or chlorambucil (CLB) are usually regarded as the most effective treatment in SLVL patients.
  • However, a few patients relapse and the second line therapy remains questionable.
  • Although 2-Cda has been evaluated in patients with chronic lymphoid leukemia (CLL) and hairy cell leukemia (HCL), it has been reported as the treatment of SLVL in only one case report.
  • The median duration between diagnosis and treatment was 18 months (range, 1 to 59).
  • The patients received 2-CdA (0.1 mg/kg/d) by venous infusion for 7 days with a median number of 1 cycle (range, 1 to 2) either as a first line therapy (one patient) or after a failure of other therapies (splenectomy, chemotherapy).
  • The treatment was not well tolerated with many infectious events.
  • In the limits of our study, 2-Cda does not appear to be efficient therapy for SLVL and is not well tolerated for patients in relapse after splenectomy or resistant to CLB.
  • [MeSH-major] Adenosine Triphosphate / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Cladribine / pharmacokinetics. Lymphoma, B-Cell / drug therapy. Splenic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Therapeutic Equivalency. Treatment Outcome

  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426611.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / cladribine triphosphate; 47M74X9YT5 / Cladribine; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


5. Gordon MM, Lucie N, Porter D: Acquired C1q deficiency caused by monoclonal paraproteinaemia. Lupus; 2000;9(1):68-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some patients with acquired C1 inhibitor deficiency are found to have an underlying malignancy, most commonly lymphoma.
  • We report a case of a 40-year-old man presenting with a lupus-like illness with acquired C1q deficiency secondary to a monoclonal paraprotein in the presence of splenic lymphoma with villous lymphocytes.
  • There was no improvement in his clinical condition following combination chemotherapy.
  • [MeSH-major] Complement C1q / deficiency. Lymphoma / complications. Paraproteinemias / complications. Splenic Neoplasms / complications
  • [MeSH-minor] Adult. Complement C3 / analysis. Complement C4 / analysis. Glucocorticoids / therapeutic use. Humans. Male. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - C1q deficiency.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10713650.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Complement C3; 0 / Complement C4; 0 / Glucocorticoids; 80295-33-6 / Complement C1q; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


6. Lazaridis KN, Abraham SC, Kamath PS: Hematological malignancy manifesting as ascites. Nat Clin Pract Gastroenterol Hepatol; 2005 Feb;2(2):112-6; quiz 117
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIAGNOSIS: Primary splenic lymphoma with hepatic infiltration causing portal hypertension and ascites.
  • MANAGEMENT: Paracentesis, dietary sodium restriction and diuretics, splenectomy, splenorenal shunt and chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone).
  • [MeSH-major] Ascites / etiology. Hematologic Neoplasms / complications. Hematologic Neoplasms / diagnosis. Hypersplenism / etiology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Hypertension, Portal / etiology. Middle Aged. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265129.001).
  • [ISSN] 1743-4378
  • [Journal-full-title] Nature clinical practice. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Clin Pract Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Han SM, Teng CL, Hwang GY, Chou G, Tsai CA: Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture. J Chin Med Assoc; 2008 Apr;71(4):210-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture.
  • Primary splenic lymphoma (PSL) is a rare disease with ambiguous definition, comprising less than 1% of non-Hodgkin's lymphoma.
  • Refusing diagnostic splenectomy, he received chemotherapy.
  • Spontaneous splenic rupture occurred after chemotherapy.
  • He received another 5 courses of chemotherapy with the R-CNOP regimen (rituximab, cyclophosphamide, mitoxantrone, vincristine, prednisolone).
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / complications. Lymphoma, Large B-Cell, Diffuse / complications. Splenic Neoplasms / complications. Splenic Rupture / etiology

  • Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436505.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Moghazy KM: Gastrosplenic fistula following chemotherapy for lymphoma. Gulf J Oncolog; 2008 Jan;(3):64-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrosplenic fistula following chemotherapy for lymphoma.
  • Gastrosplenic fistula resulting from erosion of a primary splenic lymphoma is a very rare cause of massive upper gastrointestinal hemorrhage as compared to benign peptic ulcer disease, gastric Crohn's disease, gastric adenocarcinoma, and primary gastric and splenic lymphomas.
  • This hemorrhage can be successfully managed by splenic artery embolization, followed by splenectomy and gastric resection.
  • A 50-year-old patient developed a gastrosplenic fistula during a course of chemotherapy for differentiated histiocytic lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastric Fistula / chemically induced. Lymphoma, Large B-Cell, Diffuse / drug therapy. Splenic Diseases / chemically induced
  • [MeSH-minor] Humans. Laparotomy. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084800.001).
  • [ISSN] 2078-2101
  • [Journal-full-title] The Gulf journal of oncology
  • [ISO-abbreviation] Gulf J Oncolog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kuwait
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Lefrère F, Hermine O, Belanger C, François S, Tilly H, Lebas de La Cour JC, Valensi F, Varet B, Troussard X: Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia; 2000 Apr;14(4):573-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is a B cell chronic lymphoproliferative disorder.
  • Splenectomy and/or chlorambucil are usually regarded as the most effective treatment in SLVL patients.
  • However, a few patients relapse and the second-line treatment remains questionable.
  • The median duration between diagnosis and treatment was 17 months (range, 1-30).
  • The patients received FDR 25 mg/m2/day by venous infusion for 5 days with a median of four cycles of chemotherapy (range, 2-6).
  • The treatment was well tolerated.
  • FDR appears to be an efficient therapy with a favorable toxicity profile for patients in relapse after splenectomy or resistant to CLB.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Lymphoma, B-Cell / drug therapy. Splenic Neoplasms / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chlorambucil / therapeutic use. Combined Modality Therapy. Drug Evaluation. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Retrospective Studies. Splenectomy

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764141.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Immunologic Factors; 0 / Interferon-alpha; 18D0SL7309 / Chlorambucil; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


10. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic lymphoma: an elusive preoperative diagnosis.
  • Four patients underwent splenectomy for various clinical and radiological diagnoses and were found to have primary splenic lymphoma at surgery and histology.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • The first two patients had multiple nodules in the spleen measuring 0.1-0.5 cm while large cell lymphomas had large nodules (largest measuring 11 cm x 7 cm x 4 cm).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


11. Khan F, Vessal S, McKimm E, D'Souza R: Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma.
  • A gastrosplenic fistula is a rare complication of gastric and splenic lymphomas which can occur spontaneously or secondary to chemotherapy.
  • We report a case of a spontaneous gastrosplenic fistula secondary to a diffuse splenic large B cell lymphoma in a previously well 43-year-old patient.
  • CT imaging demonstrated the fistula, which was subsequently managed with chemotherapy.
  • [MeSH-major] Fistula / etiology. Fistula / radiography. Gastric Fistula / etiology. Gastric Fistula / radiography. Image Interpretation, Computer-Assisted. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / radiography. Multidetector Computed Tomography. Splenic Diseases / etiology. Splenic Diseases / radiography. Splenic Neoplasms / complications. Splenic Neoplasms / radiography
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cooperative Behavior. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interdisciplinary Communication. Methotrexate / administration & dosage. Patient Care Team. Radiographic Image Enhancement. Rituximab. Spleen / pathology. Spleen / radiography. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 2002 Aug;95(8):941-2 [12190240.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):287-90 [17098664.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):994-6 [6349784.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Saudi Med J. 2007 Dec;28(12):1898-900 [18060225.001]
  • [Cites] Ann Hematol. 2008 Apr;87(4):337-8 [17929016.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):69-70 [18386245.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Jan;101(1):76-8 [19335040.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Mar;101(3):222-3 [19388805.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):e15-7 [19433680.001]
  • [Cites] Abdom Imaging. 2002 Nov-Dec;27(6):728-30 [12395264.001]
  • [Cites] Dis Colon Rectum. 1986 Aug;29(8):521-3 [3755392.001]
  • [Cites] Mayo Clin Proc. 1989 Jul;64(7):776-9 [2770360.001]
  • [Cites] Comput Med Imaging Graph. 1990 Jul-Aug;14(4):273-6 [2383867.001]
  • [Cites] J Clin Gastroenterol. 1991 Aug;13(4):478-81 [1918860.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):587-9 [8674934.001]
  • [Cites] J Thorac Imaging. 1996 Spring;11(2):150-2 [8820024.001]
  • [Cites] Am Surg. 1997 Nov;63(11):1007-10 [9358792.001]
  • [Cites] Gulf J Oncolog. 2008 Jan;(3):64-7 [20084800.001]
  • (PMID = 22791483.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  • [Other-IDs] NLM/ PMC3029570
  •  go-up   go-down


12. Zhang R, Wang D, Li Q, Sun T, Hao X: [Primary lymphoma of the spleen: clinical analysis of 23 cases]. Zhonghua Wai Ke Za Zhi; 2002 Mar;40(3):208-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the spleen: clinical analysis of 23 cases].
  • OBJECTIVE: To investigate the best diagnostic and therapeutic method for primary lymphoma of the spleen.
  • They accepted chemotherapy after operation.
  • B-cell type non-Hodgkin's lymphoma was noted in 21 patients and T-cell letion in 2.
  • CONCLUSIONS: The diagnosis of splenic lymphoma is dependent mainly on B-ultrasound examination and CT scanning.
  • Splenectomy combined with chemotherapy may provide optimum therapy for patients with splenic lymphoma.
  • [MeSH-major] Lymphoma / surgery. Splenic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Splenectomy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11955418.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Koch CA, Pacak K: Abnormal ACTH-stimulation test in a patient with AIDS: adrenal insufficiency or toxoplasmosis? Endocr Regul; 2001 Jun;35(2):91-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On further evaluation, he was found to have recurrent Non-Hodgkin lymphoma (spleen) and intracranial toxoplasmosis, perhaps imitating or aggravating symptoms suggestive of adrenal insufficiency (AI).
  • We diagnosed secondary AI due to megace treatment and tapered this medication under simultaneous hydrocortisone replacement therapy.
  • We conclude that patients with AIDS on megace therapy should receive special attention in regards to the potential development of AI, especially in stress situations such as infections or pain.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Adrenal Insufficiency / diagnosis. Adrenocorticotropic Hormone. Toxoplasmosis, Cerebral / diagnosis
  • [MeSH-minor] Adult. Anti-Infective Agents / therapeutic use. Diagnosis, Differential. Humans. Male. Megestrol Acetate / antagonists & inhibitors. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11563937.001).
  • [ISSN] 1210-0668
  • [Journal-full-title] Endocrine regulations
  • [ISO-abbreviation] Endocr Regul
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 9002-60-2 / Adrenocorticotropic Hormone; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


14. Puli SR, Farrell JS, Alpert MA: Isolated gastric varices occurring 5 years after chemotherapy for splenic lymphoma. Ann Intern Med; 2004 Jun 15;140(12):1062-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated gastric varices occurring 5 years after chemotherapy for splenic lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Esophageal and Gastric Varices / etiology. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy. Splenic Vein. Vascular Diseases / complications
  • [MeSH-minor] Aged. Humans. Inflammation / complications. Male. Time Factors

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197032.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Kim JK, Hahn JS, Kim GE, Yang WI: Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma. Yonsei Med J; 2005 Oct 31;46(5):703-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma.
  • Primary splenic lymphoma (PSL) is often defined as generalized lymphoma with splenic involvement as the dominant feature.
  • It is a rare disease that comprises approximately 1% of all malignant lymphomas.
  • We investigated three cases of non-Hodgkin's splenic lymphoma that had different clinical features on presentation.
  • The patients' survival times from diagnosis ranged from 59 to 143 months, without evidence of relapse after splenectomy and chemotherapy, with or without radiotherapy.
  • Further studies are needed to evaluate the impact that different treatment modalities without splenectomy have on patient survival.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Haematol. 2000 Mar;64(3):145-50 [10997879.001]
  • [Cites] Am J Clin Pathol. 1965 Apr;43:332-3 [14275850.001]
  • [Cites] Cancer. 1966 Apr;19(4):461-9 [5327041.001]
  • [Cites] Arch Intern Med. 1971 Feb;127(2):259-65 [5101153.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1606-19 [6548171.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Cancer. 1988 Oct 1;62(7):1433-8 [3416282.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2612-9 [2249201.001]
  • [Cites] Am J Hematol. 1991 Oct;38(2):95-100 [1951314.001]
  • [Cites] Surgery. 1992 Feb;111(2):224-7 [1736393.001]
  • [Cites] J Nucl Med. 1992 Jun;33(6):1183-5 [1597736.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):207-15 [8416717.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):286-93 [7926983.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] Clin Radiol. 1998 Feb;53(2):137-42 [9502091.001]
  • [Cites] Surg Gynecol Obstet. 1965 May;120:947-60 [14269844.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3731-3 [11054447.001]
  • (PMID = 16259071.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2810579
  •  go-up   go-down


16. Elmahy H, Hawley I, Beard J: Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination. Int J Lab Hematol; 2007 Dec;29(6):461-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination.
  • The simultaneous occurrence of Hodgkin lymphoma with a variety of B-cell Non-Hodgkin lymphomas (composite lymphoma) has been described.
  • We report the first case of composite Hodgkin lymphoma and splenic marginal zone lymphoma occurring simultaneously in the same lymph node of a 64-year-old man who presented with cervical and axillary lymphadenopathy and massive splenomegaly.
  • However, cervical lymph node biopsy showed classic Hodgkin lymphoma.
  • His splenomegaly showed only a partial response to six cycles of ABVD chemotherapy so he underwent splenectomy with biopsy of remaining nodes.
  • Histology of the spleen and nodes showed splenic marginal zone lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bleomycin / administration & dosage. Bone Marrow Cells / pathology. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymph Nodes / pathology. Lymphocytes / pathology. Lymphocytosis / pathology. Lymphocytosis / therapy. Male. Middle Aged. Splenectomy. Splenomegaly / pathology. Splenomegaly / therapy. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988302.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


17. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ: Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer; 2006 Jul 1;107(1):125-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
  • BACKGROUND: The optimal management of patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) is controversial.
  • The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone.
  • METHODS: The Leukemia Service database was searched for patients with splenic lymphoma who were registered between May 1995 and October 2004.
  • The indications for treatment were the same as those used for patients with chronic lymphocytic leukemia.
  • Forty-three patients required systemic therapy; rituximab in 26 patients, chemotherapy plus rituximab in 6 patients, and chemotherapy alone in 11 patients.
  • The overall response rates were 88% with rituximab, 83% with rituximab plus chemotherapy, and 55% with chemotherapy alone; the 3-year survival rates were 95%, 100%, and 55%, respectively.
  • The 3-year failure-free survival (FFS) rates were 86%, 100%, and 45% in the rituximab, rituximab plus chemotherapy, and chemotherapy alone groups, respectively.
  • Rituximab treatments resulted in longer survival and FFS compared with chemotherapy.
  • In univariate analysis, younger age and rituximab-based therapy were predictive of longer FFS.
  • CONCLUSIONS: Rituximab with or without chemotherapy was found to have major activity in patients with SMZL.
  • Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / blood. Antineoplastic Agents / therapeutic use. Databases as Topic. Demography. Humans. Middle Aged. Retrospective Studies. Rituximab. Splenectomy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700034.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


18. Gotlib V, Singareddy S, Gergis U, Vakios J, Guevara E, Chadburn A, Yavorkovsky LL, Patel A, Butt A, Nayak A: Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes. Leuk Lymphoma; 2002 Jun;43(6):1337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is an indolent hematological malignancy.
  • Organ involvement other than spleen and bone marrow is rare in SLVL.
  • Morphologic examination and immunophenotypic analyses were conducted to determine the nature of atypical lymphocytes in the peripheral blood, spleen, bone marrow and CSF.
  • The patient improved after treatment with a combination of radiation and chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Meninges / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebrospinal Fluid / cytology. Cranial Irradiation. Cyclophosphamide / administration & dosage. Dexamethasone / therapeutic use. Erythrocyte Transfusion. Humans. Lymphocytosis / etiology. Magnetic Resonance Imaging. Male. Neoplastic Stem Cells / pathology. Prednisone / administration & dosage. Vincristine / administration & dosage. Vitamin B 12 / therapeutic use. Vitamin B 12 Deficiency / complications. Vitamin B 12 Deficiency / drug therapy

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153005.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; P6YC3EG204 / Vitamin B 12; VB0R961HZT / Prednisone; COP protocol 2
  • [Number-of-references] 9
  •  go-up   go-down


19. Dai MS, Chao TY, Yu CY: Calcification in splenic lymphoma before chemotherapy. South Med J; 2003 Aug;96(8):836-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcification in splenic lymphoma before chemotherapy.
  • [MeSH-major] Calcinosis / etiology. Lymphoma, B-Cell / complications. Lymphoma, Non-Hodgkin / complications. Splenic Diseases / etiology. Splenic Neoplasms / complications
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Causality. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14515933.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Yasukawa M, Yamauchi H, Azuma T, Takada K, Ishimura M, Fujita S: Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur J Haematol; 2002 Aug;69(2):112-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is an indolent lymphoproliferative disorder of mature B lymphocytes.
  • Splenectomy is primarily recommended for treating this disease, and splenic irradiation or alkylating agents may be effective; however, frequent recurrence is observed after these therapies.
  • Although the effects of splenic irradiation and combination chemotherapy were both unsatisfactory and transient, complete remission lasting for more than 15 months was achieved after two courses of treatment with low-dose fludarabine (15 mg m(-2) daily for 3 d).
  • The present case indicates that treatment with fludarabine is effective for SLVL and recommended as the first-line therapy for elderly patients and those with an aggressive form of the disease.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12366716.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


21. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M: Marginal zone-related neoplasms of splenic and nodal origin. Haematologica; 2003 Jan;88(1):80-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone-related neoplasms of splenic and nodal origin.
  • BACKGROUND: The marginal zone is an anatomically distinct B-cell compartment of lymphoid tissue with an abundant antigenic influx.
  • Among marginal zone-derived lymphomas the WHO classification listed, in addition to extranodal marginal zone B-cell lymphoma of MALT type, two other marginal zone B-cell neoplasms: splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) and nodal marginal zone B-cell lymphoma (+/- monocytoid B cells).
  • Treatment options are heterogeneous, including a watch-and-wait policy, surgery with or without chemotherapy, purine analogs, and interferon.
  • STATE OF THE ART: Splenic and nodal marginal zone lymphomas are typical low-grade lymphomas with an indolent course.
  • The role played by hepatitis C virus (HCV) in marginal zone lymphomas is not fully elucidated, but there is demonstration that eradication of HCV infection in splenic lymphoma with villous lymphocytes causes regression of the lymphoma.
  • The optimal treatment has not yet been identified.
  • Retrospective series, however, show that splenectomy is a good option if symptoms from the presence of spleen enlargement or cytopenias need to be treated.
  • The optimal therapeutic approach and the role of new treatments need to be assessed in prospective clinical trials.
  • [MeSH-major] Lymphoma, B-Cell / pathology
  • [MeSH-minor] Humans. Lymph Nodes / pathology. Prognosis. Spleen / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12551831.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 95
  •  go-up   go-down


22. Harada S, Kalla H, Balasubramanian M, Brodsky I, Gladstone D, Hou JS: Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen. Ann Diagn Pathol; 2008 Jun;12(3):212-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen.
  • Combination of the splenic marginal zone B-cell lymphoma (SMZL) and classical Hodgkin lymphoma (cHL) is extremely rare.
  • After the chemotherapy, the patient achieved a clinical/radiologic remission, whereas cHL was detected in liver and bone marrow subsequently.
  • The case indicates that both components of lymphoma can present concurrently as a composite form of lymphoma and both need to be treated adequately.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. B-Lymphocytes / chemistry. B-Lymphocytes / pathology. Combined Modality Therapy. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Lymphatic Diseases. Male. Middle Aged. Reed-Sternberg Cells / pathology. Remission Induction. Splenomegaly

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486899.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


23. Bronzino P, Abbo L, Bagnasco F, Barisone P, Dezzani C, Genovese AM, Iannucci P, Ippoliti M, Sacchi M, Aimo I: [Splenic marginal zone lymphoma: case report and review of the literature]. G Chir; 2005 Nov-Dec;26(11-12):419-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic marginal zone lymphoma: case report and review of the literature].
  • [Transliterated title] Linfoma splenico della marginale: descrizione di un caso clinico e revisione della letteratura.
  • Splenic marginal zone lymphomas are rare tumors which take origin from the B cells.
  • Computed tomography demonstrated splenomegaly with an area of low density in the spleen.
  • Only by laparotomy and splenectomy the correct diagnosis was possible.
  • Because of the indolent course of this kind of lymphomas, splenectomy is the main treatment for patients with abdominal pain, splenomegaly and cytopenia.
  • If there is no pain and no cytopenia, the treatment can be only wait and see.
  • Only in case of progression of disease chemotherapy can be employed.
  • [MeSH-major] Lymphoma. Splenic Neoplasms
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Laparotomy. Prognosis. Radiography, Abdominal. Spleen / pathology. Splenectomy. Splenomegaly / etiology. Splenomegaly / pathology. Splenomegaly / radiography. Splenomegaly / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472419.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Carr JA, Shurafa M, Velanovich V: Surgical indications in idiopathic splenomegaly. Arch Surg; 2002 Jan;137(1):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: The incidence of primary lymphoma of the spleen in patients with idiopathic splenomegaly is significant.
  • Of these, 18 had idiopathic splenomegaly despite prior workup with computed tomography, peripheral smear, bone marrow biopsy, and laboratory testing.
  • INTERVENTION: All 18 patients underwent open splenectomy for diagnosis and treatment of their cytopenias.
  • MAIN OUTCOME MEASURE: Incidence of lymphoma in the pathologic specimens.
  • In all 18 patients, the surgical specimen provided a diagnosis.
  • Six patients with the benign diagnosis of hypersplenism received no further interventions, and the cytopenias resolved in all 6 cases.
  • The 7 remaining patients (39%) were diagnosed with lymphoma.
  • Five had marginal zone lymphoma, and 2 had a more aggressive B-cell lymphoma.
  • Three patients required chemotherapy, but 4 are still in remission since their splenectomies and show no evidence of active disease.
  • CONCLUSIONS: A high percentage of patients with splenomegaly of unknown etiology will have primary lymphoma of the spleen.
  • Splenectomy is both diagnostic and therapeutic and should be considered for all patients with idiopathic splenomegaly.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Splenic Neoplasms / epidemiology. Splenomegaly / surgery

  • Genetic Alliance. consumer health - Splenomegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11772218.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hamblin TJ: Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs; 2001;61(5):593-611
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It needs to be distinguished from mantle cell lymphoma and splenic marginal zone lymphoma by lymphocyte markers.
  • This group of patients have a normal life expectancy and do not require treatment beyond reassurance.
  • Progression involves an increasing white cell count, enlarging lymph nodes and spleen, anaemia and thrombocytopenia.
  • Complications of progression include autoimmune haemolytic anaemia and thrombocytopenia, immunodeficiency, and the development of a more aggressive lymphoma.
  • Intermittent chlorambucil remains the first choice treatment for the majority of patients.
  • Combination chemotherapy offers no advantage.
  • Intravenous fludarabine is probably more effective than chlorambucil, but no trial has yet shown a survival advantage for using it first rather than as a salvage treatment in patients not responding to chlorambucil.
  • It is at least 40 times as expensive as chlorambucil.
  • For patients refractory to both drugs, a variety of options are available.
  • High dose corticosteroids, high dose chlorambucil, CHOP (cyclophosphamide, prednisolone, vincristine and doxorubicin), anti-CD52, anti-CD20 and a range of experimental drugs which are being evaluated in clinical trials.
  • Younger patients should be offered the chance of treatment with curative intent, preferably in the context of a clinical trial.
  • Only time will tell whether some of these patients are cured but it seems unlikely.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1574-9 [10334546.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1885-9 [9586905.001]
  • [Cites] Am J Hematol. 1988 Nov;29(3):152-63 [3189311.001]
  • [Cites] Clin Exp Immunol. 1966 Jan;1(1):3-11 [5953036.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2107-14 [9179056.001]
  • [Cites] Br J Cancer. 1990 Jul;62(1):4-5 [2390480.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:89-91 [27463486.001]
  • [Cites] Hematol Cell Ther. 1998 Jun;40(3):113-8 [9698219.001]
  • [Cites] Br J Ophthalmol. 2000 Jan;84(1):117 [10691327.001]
  • [Cites] Acta Oncol. 1995;34(4):536-7 [7605666.001]
  • [Cites] N Engl J Med. 1990 Dec 20;323(25):1729-35 [2247105.001]
  • [Cites] N Engl J Med. 1988 Oct 6;319(14 ):902-7 [2901668.001]
  • [Cites] Am J Hematol. 1999 Feb;60(2):99-104 [9929100.001]
  • [Cites] Leuk Res. 1999 Mar;23(3):277-9 [10071081.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):359-61 [3222145.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):65-74 [9482528.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):983-8 [7707127.001]
  • [Cites] Medicine (Baltimore). 1986 Sep;65(5):339-51 [3091991.001]
  • [Cites] J Clin Oncol. 1984 Aug;2(8):881-91 [6379121.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2313-20 [9667245.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]
  • [Cites] Am J Clin Pathol. 1997 Oct;108(4):378-82 [9322589.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3 Suppl 3):14-21 [9685175.001]
  • [Cites] Immunol Rev. 1998 Apr;162:247-59 [9602369.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1196-201 [2993534.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1130-5 [7630184.001]
  • [Cites] J Allergy Clin Immunol. 1996 Apr;97(4):998-1008 [8655897.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1365-74 [8695855.001]
  • [Cites] Cancer. 1977 Aug;40(2):855-64 [890666.001]
  • [Cites] Blood. 1993 Feb 1;81(3):597-601 [8094016.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):151-7 [10350343.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):437-42 [3065740.001]
  • [Cites] Baillieres Clin Haematol. 1993 Dec;6(4):849-66 [8038493.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1425-32 [8111709.001]
  • [Cites] Am J Hematol. 1995 Jun;49(2):135-42 [7771465.001]
  • [Cites] Clin Lab Haematol. 1997 Jun;19(2):151-2 [9218157.001]
  • [Cites] N Engl J Med. 1993 Mar 18;328(11):813-4 [8094890.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):362-3 [10355587.001]
  • [Cites] Ann Hematol. 1997 Nov-Dec;75(5-6):227-30 [9433380.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):177-88 [8546551.001]
  • [Cites] Am J Med. 1990 Sep;89(3):388-90 [1697447.001]
  • [Cites] Cancer. 1973 Mar;31(3):502-8 [4693581.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1104-8 [7850708.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):509-14 [8882965.001]
  • [Cites] Br J Haematol. 1981 Apr;47(4):529-37 [7213576.001]
  • [Cites] Leukemia. 1997 Jan;11(1):170 [9001435.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]
  • [Cites] Br J Haematol. 1986 Jun;63(2):377-87 [3487341.001]
  • [Cites] Eur J Haematol. 1997 Feb;58(2):109-13 [9111592.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):242-6 [10589081.001]
  • [Cites] Tumori. 1995 Nov-Dec;81(6):419-23 [8804467.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4259-64 [8943862.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2431-48 [7666104.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1569-73 [1679357.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):27-31 [10634642.001]
  • [Cites] Br J Haematol. 1986 Mar;62(3):567-75 [3954968.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):836-7 [10469479.001]
  • [Cites] Ann Pharmacother. 1992 Jul-Aug;26(7-8):939-47 [1504408.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):433-8 [2784491.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):140-4 [2112977.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):300-1 [7612497.001]
  • [Cites] J Natl Cancer Inst. 1990 Sep 5;82(17):1416-20 [2388293.001]
  • [Cites] N Engl J Med. 1991 Jul 11;325(2):81-6 [1904989.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):720-4 [2201915.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3209-10 [9738600.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):649-52 [7819085.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):826-8 [8536738.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1112-3 [9734670.001]
  • [Cites] Sangre (Barc). 1997 Jun;42(3):254-6 [9381277.001]
  • [Cites] N Engl J Med. 1992 Oct 8;327(15):1056-61 [1355853.001]
  • [Cites] Novartis Found Symp. 1998;215:200-11; discussion 211-30 [9760581.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Nephrol Dial Transplant. 1996 Nov;11(11):2306-8 [8941597.001]
  • [Cites] Lancet. 1993 Aug 28;342(8870):555 [8102691.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):730-1 [8664199.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):80-97 [9482530.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):341-4 [8547072.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):121-6 [8641639.001]
  • [Cites] Concepts Immunopathol. 1987;4:24-41 [2885092.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):677-9 [9531333.001]
  • [Cites] Ann Oncol. 1995 May;6(5):421-33 [7669706.001]
  • [Cites] Am J Pathol. 1928 Jul;4(4):285-292.7 [19969796.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):679-89 [8097528.001]
  • [Cites] Baillieres Clin Haematol. 1987 Jun;1(2):449-91 [3322445.001]
  • [Cites] Acta Haematol. 1995;93(2-4):73-9 [7543720.001]
  • [Cites] J Clin Pathol. 1995 Feb;48(2):181-2 [7745121.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Br Med J. 1973 Oct 6;4(5883):23-4 [4585418.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:133-8 [27463495.001]
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):391-8 [9684936.001]
  • [Cites] Am J Hematol. 1995 Apr;48(4):293 [7717386.001]
  • [Cites] Leukemia. 1999 Apr;13(4):518-23 [10214856.001]
  • [Cites] Am J Hematol. 1990 Sep;35(1):32-6 [2202205.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):238-9 [1457584.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):861-8 [10340906.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):748-58 [8151318.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):733-43 [3282467.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):458-65 [9053466.001]
  • [Cites] Br J Haematol. 1996 Feb;92(2):382-8 [8603004.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1144-50 [9067285.001]
  • [Cites] Br Med J. 1974 Sep 14;3(5932):655-7 [4279123.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Ann Hematol. 2000 Jan;79(1):43-5 [10663621.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2455-7 [10787241.001]
  • [Cites] Ann Intern Med. 1996 Feb 1;124(3):311-5 [8554226.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):833-4 [1697401.001]
  • [Cites] Br J Cancer. 1984 May;49(5):547-57 [6722005.001]
  • [Cites] Leuk Lymphoma. 1993 Sep;11(1-2):63-8 [8220155.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):319-22 [7904047.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):117-22 [10052715.001]
  • [Cites] Ann Oncol. 1992 Feb;3(2):171-2 [1606091.001]
  • (PMID = 11368285.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 156
  •  go-up   go-down


26. Iriyama N, Horikoshi A, Hatta Y, Kobayashi Y, Sawada S, Takeuchi J: Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy. Intern Med; 2010;49(11):1027-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy.
  • Herein we report a case of a localized, massive, diffuse large B-cell splenic lymphoma diagnosed by splenectomy.
  • Enhanced computed tomography scanning showed an irregularly enhanced effect in the spleen suggesting a diffuse splenic tumor.
  • The resected spleen weighed 3,500 g.
  • After the operation, the patient recovered from the pancytopenia and pathology diagnosed diffuse large B-cell lymphoma.
  • Standard CHOP plus rituximab chemotherapy was given.
  • [MeSH-major] Hypersplenism / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenectomy / adverse effects. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519821.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Eloubeidi MA, Varadarajulu S, Eltoum I, Jhala D, Chhieng DC, Jhala NC: Transgastric endoscopic ultrasound-guided fine-needle aspiration biopsy and flow cytometry of suspected lymphoma of the spleen. Endoscopy; 2006 Jun;38(6):617-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transgastric endoscopic ultrasound-guided fine-needle aspiration biopsy and flow cytometry of suspected lymphoma of the spleen.
  • BACKGROUND AND STUDY AIMS: Masses in the spleen can be sampled by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) but the diagnosis of lymphoma using EUS-FNA and flow cytometry has not been reported.
  • We report our experience with transgastric EUS-FNA and flow cytometry in the investigation of patients with suspected lymphoma of the spleen.
  • PATIENTS AND METHODS: All patients with splenic lesions that had been detected by computed tomography and who were referred for transgastric EUS-FNA over a 3-year period were enrolled in this study.
  • The tissue obtained by EUS-FNA was evaluated by flow cytometry in all patients.
  • RESULTS: Six patients with splenic masses were enrolled (four men, two women; median age 58.5 years, range 41 - 82 years).
  • EUS-FNA was performed successfully in all patients and the tissue obtained was evaluated by flow cytometry.
  • Two patients were diagnosed with lymphoma; no pathology was identified in the other four patients.
  • Lymphoma of the spleen appeared as sharply demarcated echo-poor lesions; benign lesions appeared echo-rich in comparison with the surrounding splenic tissue.
  • The two patients who were diagnosed with lymphoma underwent chemotherapy.
  • Of the four patients in whom no pathology was identified, one patient subsequently underwent splenectomy for evaluation of persistent abdominal pain and was diagnosed with lymphoma; the three other patients had true-negative disease on the evidence of long-term follow-up (mean 8 months; range 6 - 12 months).
  • No complications related to the EUS-FNA procedure were encountered in any patient.
  • CONCLUSIONS: EUS-FNA of spleen masses is a safe technique that aids in the diagnosis of lymphoma when used in conjunction with flow cytometry.
  • [MeSH-major] Endoscopy, Gastrointestinal. Endosonography. Flow Cytometry / methods. Lymphoma / pathology. Splenic Diseases / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. Stomach

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685607.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, Podevin P, Bouscary D, Sogni P, Blanche P, Dreyfus F: Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia; 2004 Oct;18(10):1711-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.
  • A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies.
  • Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection.
  • In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / pathogenicity. Hepatitis C / drug therapy. Lymphoma, B-Cell / virology
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Prospective Studies. Retrospective Studies. Ribavirin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2004 Oct;18(10):1572-5 [15284857.001]
  • (PMID = 15284859.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  •  go-up   go-down






Advertisement